Skip to content

A Comparison of Two Different Doses of Maternal B12 Supplementation in Improving Infant B12 Deficiency and Neurodevelopment

A Comparison of Two Different Doses of Maternal B12 Supplementation in Improving Infant B12 Deficiency and Neurodevelopment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04083560
Acronym
MATCOBIND
Enrollment
708
Registered
2019-09-10
Start date
2018-09-26
Completion date
2022-09-25
Last updated
2022-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin B 12 Deficiency

Brief summary

Supplementation with Iron and folate have been part of a worldwide strategy targeting anaemia and neural tube defects for many years. However, vitamin B12 deficiency has received much less attention. High prevalence of deficiency in mothers in the antenatal period and in their infants, has been documented. Multiple case series document the neurological consequences of severe deficiency and their reversal with B-12. Trials on the subject are limited and those available have either used an ineffective dose or for a short duration. Therefore, we propose this randomised controlled trial to compare the efficacy of two different doses (pharmacological and preventive) of maternal Vitamin B-12 supplementation in improving infant B12 deficiency and neurodevelopment. We propose to undertake a multi-centric trial in India and Nepal given the high prevalence of deficiency reported from these countries and to allow a wider socio-demographic spectrum (Pay-for-service hospital catering to middle income populace from India and a free-care public hospital catering to lower income groups from Nepal). We will recruit 720 vegetarian, pregnant women from the antenatal clinics of the Indian and Nepalese centres at their first antenatal visit. Elderly primi mothers, taking B12 supplementation, multiple gestations, chronic medical conditions, anticipating moving out of the city, treated for infertility or with known psychological illnesses will be excluded. In Stage 1, recruited mothers will be randomized into 2 equal groups (360 each). Group 1-Daily 250 μg Vitamin B12 supplementation. Group 2-Daily 50 μg Vitamin B12 supplementation. B-12 will be started in 1st trimester and continue up to 6 months post-partum. In Stage 2, the birth and post-delivery course of the new-born will be monitored and documented for any morbidity. At 9 months, the neurodevelopmental, complementary feeding and home environment will be assessed and infant B12 status will be determined. The two groups will be compared for the primary (neurodevelopment) and secondary outcomes (biochemical parameters in mother and infant). The results of this study will be used to generate scientific evidence on whether B-12 should be supplemented in vegetarian pregnant women with a view to preventing B-12 deficiency and its neurodevelopmental consequences in the infant.

Interventions

Vitamin B12 250mcg

Sponsors

Public Health Foundation of India
CollaboratorOTHER
Paropakar Matenity and Women's Hospital, Kathmandu, Nepal
CollaboratorUNKNOWN
University College, London
CollaboratorOTHER
Sitaram Bhartia Institute of Science and Research
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* \<12 weeks gestation Vegetarian mothers

Exclusion criteria

1. Mothers already on B12 supplementation 2. Women with multiple gestation, those diagnosed with chronic medical conditions (diabetes mellitus, hypertension, heart disease, neurological disease or thyroid disease), and those who tested positive for hepatitis B, HIV or syphilis (associated with prematurity, IUGR and other neonatal morbidities which could influence neurodevelopment) 3. Women who anticipate moving out of the city before/ after delivery 4. Women treated for infertility 5. Women with known psychological illnesses including depression

Design outcomes

Primary

MeasureTime frameDescription
Infant neurodevelopment9 Month of infant ageDevelopmental Assessment Scale for Indian Infant (modified Bayleys scale) measured as average of motor and mental scores

Secondary

MeasureTime frameDescription
Biochemical B12 status of motherAt recruitmentChange in B12 status of mother between first and third trimester
Biochemical B12 status of infant9 months of infant ageBiochemical B12 status of infant at nine months postpartum

Other

MeasureTime frameDescription
Mean Haemoglobin of infants9 months of infant ageHaemoglobin of infants in grams per deciliter
Infant head circumference9 months of infant ageInfant Head circumference in cms
Infant weight9 months of infant ageInfant weight in kilograms
Infant length9 months of infant ageInfant Length in cms

Countries

India, Nepal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026